<SEC-DOCUMENT>0000899243-23-019706.txt : 20231003
<SEC-HEADER>0000899243-23-019706.hdr.sgml : 20231003
<ACCEPTANCE-DATETIME>20231003083558
ACCESSION NUMBER:		0000899243-23-019706
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20231002
FILED AS OF DATE:		20231003
DATE AS OF CHANGE:		20231003

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			BRUKER CORP
		CENTRAL INDEX KEY:			0001109354
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39388
		FILM NUMBER:		231301617

	BUSINESS ADDRESS:	
		STREET 1:		40 MANNING RD
		CITY:			BILLERICA
		STATE:			MA
		ZIP:			01821
		BUSINESS PHONE:		978663-3660

	MAIL ADDRESS:	
		STREET 1:		40 MANNING RD
		CITY:			BILLERICA
		STATE:			MA
		ZIP:			01821

	FORMER NAME:	
		FORMER CONFORMED NAME:	BRUKER BIOSCIENCES CORP
		DATE OF NAME CHANGE:	20030721

	FORMER NAME:	
		FORMER CONFORMED NAME:	BRUKER DALTONICS INC
		DATE OF NAME CHANGE:	20000315

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bruker Cellular Analysis, Inc.
		CENTRAL INDEX KEY:			0001689657
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				352415390
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		5858 HORTON STREET
		STREET 2:		SUITE 320
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-858-2855

	MAIL ADDRESS:	
		STREET 1:		5858 HORTON STREET
		STREET 2:		SUITE 320
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PhenomeX Inc.
		DATE OF NAME CHANGE:	20230320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Berkeley Lights, Inc.
		DATE OF NAME CHANGE:	20161109
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-10-02</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001689657</issuerCik>
        <issuerName>Bruker Cellular Analysis, Inc.</issuerName>
        <issuerTradingSymbol>CELL</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001109354</rptOwnerCik>
            <rptOwnerName>BRUKER CORP</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>40 MANNING ROAD</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>BILLERICA</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>01821</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-10-02</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>1000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>99711.327</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1000</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">On August 17, 2023, the Issuer entered into an Agreement and Plan of Merger (the &quot;Merger Agreement&quot;) with Bruker Corporation (&quot;Bruker&quot;) and Bird Mergersub Corporation, a wholly owned subsidiary of Bruker (&quot;Purchaser&quot;). The Merger Agreement provided that Bruker will acquire the Issuer through a cash tender offer (the &quot;Offer&quot;) by Purchaser for all of the Issuer's outstanding shares of common stock, par value $0.00005 per share.</footnote>
        <footnote id="F2">As of one minute past 11:59 p.m., New York City time, on September 28, 2023, the Offer expired and Purchaser accepted for purchase a total of 81,254,441 shares validly tendered and not validly withdrawn, representing approximately 81.5% of the outstanding shares of the Issuer. Following the expiration of the Offer, Purchaser merged with and into the Issuer on October 2, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Purchaser issued and outstanding immediately before October 2, 2023 automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the Issuer (representing 1,000 shares in the aggregate) (the &quot;Merger&quot;), with the Issuer surviving as a wholly owned subsidiary of Bruker. As a result of the Offer and the Merger, Bruker acquired a total of 1,000 shares of common stock in exchange for $99,711,327 in cash.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ J. Brent Alldredge, Senior Vice President, General Counsel and Corporate Secretary, on behalf of Bruker Corporation</signatureName>
        <signatureDate>2023-10-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
